IRIS
PATRIARCA, Francesca
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 12.541
AS - Asia 4.814
EU - Europa 3.403
SA - Sud America 1.111
AF - Africa 82
Continente sconosciuto - Info sul continente non disponibili 16
OC - Oceania 6
Totale 21.973
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 12.381
SG - Singapore 2.321
CN - Cina 1.088
UA - Ucraina 1.062
BR - Brasile 946
HK - Hong Kong 571
DE - Germania 542
IT - Italia 400
FI - Finlandia 360
VN - Vietnam 353
RU - Federazione Russa 297
SE - Svezia 241
IE - Irlanda 200
CA - Canada 102
GB - Regno Unito 102
TR - Turchia 94
IN - India 88
KR - Corea 70
AR - Argentina 64
BD - Bangladesh 42
IQ - Iraq 35
AT - Austria 30
MX - Messico 30
NL - Olanda 28
CO - Colombia 27
PL - Polonia 27
EC - Ecuador 25
FR - Francia 22
IR - Iran 21
ZA - Sudafrica 21
BE - Belgio 20
ID - Indonesia 18
JP - Giappone 17
PY - Paraguay 15
EU - Europa 14
CZ - Repubblica Ceca 12
MA - Marocco 12
ES - Italia 10
RO - Romania 10
UZ - Uzbekistan 10
KE - Kenya 9
PE - Perù 9
PK - Pakistan 9
SA - Arabia Saudita 9
VE - Venezuela 9
AZ - Azerbaigian 8
CL - Cile 8
TG - Togo 8
AE - Emirati Arabi Uniti 7
AU - Australia 6
CH - Svizzera 6
JM - Giamaica 6
RS - Serbia 6
AL - Albania 5
DZ - Algeria 5
EG - Egitto 5
KG - Kirghizistan 5
NP - Nepal 5
TN - Tunisia 5
BG - Bulgaria 4
GA - Gabon 4
HN - Honduras 4
IL - Israele 4
JO - Giordania 4
KZ - Kazakistan 4
LT - Lituania 4
OM - Oman 4
PA - Panama 4
UY - Uruguay 4
MY - Malesia 3
PS - Palestinian Territory 3
SN - Senegal 3
AM - Armenia 2
BA - Bosnia-Erzegovina 2
BB - Barbados 2
BH - Bahrain 2
BO - Bolivia 2
BY - Bielorussia 2
CM - Camerun 2
DO - Repubblica Dominicana 2
GE - Georgia 2
GT - Guatemala 2
GY - Guiana 2
KH - Cambogia 2
LB - Libano 2
LV - Lettonia 2
SY - Repubblica araba siriana 2
TT - Trinidad e Tobago 2
TW - Taiwan 2
BZ - Belize 1
CI - Costa d'Avorio 1
CR - Costa Rica 1
CU - Cuba 1
CV - Capo Verde 1
CW - ???statistics.table.value.countryCode.CW??? 1
CY - Cipro 1
DK - Danimarca 1
EE - Estonia 1
ET - Etiopia 1
GD - Grenada 1
Totale 21.952
Salva come PNG Salva come JPEG
Città #
Fairfield 1.589
Woodbridge 1.361
Houston 1.003
Ashburn 952
Singapore 915
Ann Arbor 893
Jacksonville 701
Wilmington 644
Seattle 637
Beijing 585
Hong Kong 571
Chandler 569
Cambridge 509
Dearborn 454
Boardman 269
Dallas 225
Princeton 211
Dublin 199
Udine 147
Los Angeles 132
Ho Chi Minh City 124
San Diego 99
Buffalo 92
Hefei 89
São Paulo 87
Redondo Beach 79
Izmir 78
Dong Ket 69
Seoul 67
Munich 66
Hanoi 57
New York 55
Ogden 51
Des Moines 44
Norwalk 43
Ottawa 40
Nuremberg 35
Rio de Janeiro 31
Kunming 27
Montreal 27
Turku 27
Nanjing 26
Trieste 26
Mumbai 24
Warsaw 23
Belo Horizonte 21
Santa Clara 21
Lappeenranta 19
Redmond 19
Brasília 18
Brussels 18
Curitiba 18
Guangzhou 18
Denver 17
Frankfurt am Main 17
Haiphong 16
Toronto 16
Atlanta 15
Chicago 15
Nanchang 15
Poplar 15
Rome 15
Salvador 15
Stockholm 15
Bogotá 14
Chennai 14
Dhaka 14
Hyderabad 13
Simi Valley 13
Boston 12
Council Bluffs 12
Da Nang 12
Düsseldorf 12
Phoenix 12
Porto Alegre 12
Vienna 12
Baghdad 11
Brooklyn 11
Campinas 11
Duino-Aurisina 11
Shanghai 11
Shenyang 11
Tokyo 11
Chengdu 10
Johannesburg 10
Leawood 10
Tashkent 10
Amsterdam 9
Ankara 9
Falls Church 9
Fortaleza 9
Fuzhou 9
Guayaquil 9
Helsinki 9
London 9
Redwood City 9
Venezia 9
Washington 9
Caxias do Sul 8
Jinan 8
Totale 14.659
Salva come PNG Salva come JPEG
Nome #
Prognostic significance of the detection of tumour cells in peripheral blood stem cell collections in stage II and III breast cancer patients treated with high-dose therapy 270
Combined orthotopic heart transplantation followed by autologous stem cell transplantation in a patient with light chain amyloidosis and isolated cardiac involvement 206
Activity of all-trans-retinoic acid in a case of central nervous system extramedullary relapse of acute promyelocytic leukemia 193
Minimal residual disease after transplantation or lenalidomide-based consolidation in myeloma patients: a prospective analysis 188
Anti-CD20 therapy for chronic lymphocytic leukemia-associated autoimmune diseases 185
Allogeneic hematopoietic stem cell transplantation in myelofibrosis: the 20-year experience of the Gruppo Italiano Trapianto di Midollo Osseo (GITMO)” 182
Allogeneic hematopoietic cell transplantation from unrelated donors in multiple myeloma: study from the Italian Bone Marrow Donor Registry. 179
The development of autoantibodies after allogeneic stem cell transplantation is related with chronic graft-vs-host disease and immune recovery 173
B-cell immune reconstitution after allogenic stem cell transplantation and its role in the development of chronic graft-versus-host disease 170
18F-FDG PET/CT focal, but not osteolytic, lesions predict the progression of smoldering myeloma to active disease 169
The role of positron emission tomography with 18F-fluorodeoxyglucose integrated with computed tomography in the evaluation of patients with multiple myeloma undergoing allogeneic stem cell transplantation 164
The genetic and genomic background of multiple myeloma patients achieving complete response after induction therapy with bortezomib, thalidomide and dexamethasone (VTD). 159
Predictive value of pretransplantation molecular minimal residual disease assessment by WT1 gene expression in FLT3-positive acute myeloid leukemia 159
Allogeneic stem cell transplantation in multiple myeloma relapsed after autograft: A multicenter retrospective study based on donor availability 158
Allogeneic Stem Cell Transplantation for Relapsed/Refractory B Cell Lymphomas: Results of a Multicenter Phase II Prospective Trial including Rituximab in the Reduced-Intensity Conditioning Regimen. 157
A comparison of allografting with autografting for newly diagnosed myeloma 154
Impact of hepatitis C virus infection on clinical features, quality of life and survival of patients with lymphoplasmacytoid lymphoma/immunocytoma 151
Earlier administration of Rituximab allows higher rate of long-lasting response in adult patients with autoimmune thrombocytopenia 151
Clinical feature and outcome in seven patients wuth hyaline or mixed variant of Castleman’s disease. A single centre experience 150
Bortezomib-melphalan-prednisone-thalidomide followed by maintenance with bortezomib-thalidomide compared with bortezomib-melphalan-prednisone for initial treatment of multiple myeloma: updated follow-up and improved survival. 150
Once-weekly carfilzomib, pomalidomide, and low-dose dexamethasone for relapsed/refractory myeloma: a phase I/II study 150
Bortezomib-thalidomide-dexamethasone is superior to thalidomide-dexamethasone as consolidation therapy after autologous hematopoietic stem cell transplantation in patients with newly diagnosed multiple myeloma 147
Long-Term Follow-Up of a Donor versus No-Donor Comparison in Patients with Multiple Myeloma in First Relapse after Failing Autologous Transplantation 147
Prognostic factors and outcome of Epstein-Barr virus DNAemia in high-risk recipients of allogeneic stem cell transplantation treated with preemptive rituximab. 147
Busulfan- or Thiotepa-Based Conditioning in Myelofibrosis: A Phase II Multicenter Randomized Study from the GITMO Group 144
Rituximab therapy in adult patients with relapsed or refractory immune thrombocytopenic purpura: long-term follow-up results 142
Phase II trial to investigate efficacy and safety of bendamustine, dexamethasone and thalidomide in relapsed or refractory multiple myeloma patients after treatment with lenalidomide and bortezomib 142
Bendamustine in relapsed/refractory multiple myeloma: the "real-life" side of the moon. 139
Acute hepatic failure as onset of progressive sclerodermatous chronic graft-versus-host disease after donor lymphocyte infusion. 139
Bortezomib as induction before autologous transplantation, followed by lenalidomide as consolidation-maintenance in untreated multiple myeloma patients. 138
Risk Factors and Outcomes of Infections by Multidrug-Resistant Gram-Negative Bacteria in Patients Undergoing Hematopoietic Stem Cell Transplantation 137
Bortezomib-thalidomide-dexamethasone (VTD) is superior to bortezomib-cyclophosphamide-dexamethasone (VCD) as induction therapy prior to autologous stem cell transplantation in multiple myeloma. 137
Antilymphocyte Globulin for Prevention of Chronic Graft-versus-Host Disease 136
Acute myeloid leukemia following chronic low-dose cyclophosphamide in metastatic breast cancer 134
Defibrotide : review on clinical use and future development 134
Lower dose rituximab is active in adults patients with idiopathic thrombocytopenic purpura 134
Maintenance in myeloma patients achieving complete response after upfront therapy: a pooled analysis 134
Image interpretation criteria for FDG PET/CT in multiple myeloma: a new proposal from an Italian expert panel. IMPeTUs (Italian Myeloma criteria for PET USe) 133
Rituximab for the treatment of type II mixed cryoglobulinemia 131
Brentuximab vedotin in patients with Hodgkin lymphoma and a failed allogeneic stem cell transplantation: results from a named patient program at four Italian centers. 130
Continuous therapy in standard- and high-risk newly-diagnosed multiple myeloma: A pooled analysis of 2 phase III trials 130
Short-term thalidomide incorporated into double autologous stem-cell transplantation improves outcomes in comparison with double autotransplantation for multiple myeloma. 129
Busulfan plus cyclophosphamide versus busulfan plus fludarabine as a preparative regimen for allogeneic haemopoietic stem-cell transplantation in patients with acute myeloid leukaemia: an open-label, multicentre, randomised, phase 3 trial. 127
Allogeneic stem cell transplantation and novel therapies: is the treatment paradigm for younger patients with chronic lymphocytic leukemia changing? 127
CD3+ graft cell count influence on chronic GVHD in haploidentical allogeneic transplantation using post-transplant cyclophosphamide 127
Prospective molecular monitoring of minimal residual disease after non-myeloablative allografting in newly diagnosed multiple myeloma. 126
‘Real-life’ report on the management of chronic GvHD in the gruppo Italiano trapianto midollo osseo (GITMO) 126
Continuous therapy versus fixed duration of therapy in patients with newly diagnosed multiple myeloma 126
KERATOCONJUNCTIVITIS TREATMENT WITH AUTOLOGOUS SERUM EYE IN PATIENTS WITH SEVERE CHRONIC GVHD 125
T-cell chimerism and clinical outcome after reduced-intensity conditioning allogeneic stem cell transplantation 124
Efficacy and safety of peripheral blood stem cell mobilization and collection: a single-center experience in 190 allogeneic donors. 124
Acute GVHD prophylaxis plus ATLG after myeloablative allogeneic haemopoietic peripheral blood stem-cell transplantation from HLA-identical siblings in patients with acute myeloid leukaemia in remission: final results of quality of life and long-term outcome analysis of a phase 3 randomised study 124
Antimicrobial resistance in Gram-negative rods causing bacteremia in hematopoietic stem cell transplant patients: intercontinental prospective study of Infectious Diseases Working Party of the European Bone Marrow Transplantation group 124
B-cell depletion with rituximab as treatment for immune hemolytic anemia and chronic thrombocytopenia. 123
Intensified full-dose induction therapy (HD-MACHOP+radiotherapy) follwed dy consolidation with BAVC regimen and autologous stem cell transplantation as fron-line therapeutic approach for high risk aggressive non Hodgkin lymphoma 122
Flow cytometry evaluation of plasma cells contaminating leukapheresis pre- and post- CD34-positive selection- 121
Factors affecting outcome of allogeneic stem cell transplantation as salvage in patients with acute myeloid leukemia primary refractory to intensive induction therapy. 121
JAK-2 inhibitors and allogeneic transplant in myelofibrosis 121
New drugs and allogeneic hematopoietic stem cell transplantation for hematological malignancies: do they have a role in bridging, consolidating or conditioning transplantation treatment? 118
Occurrence of multiple myeloma after fludarabine treatment of a chronic lymphocytic leukemia: evidence of a biclonal derivation and clinical response to autologous transplantation 117
Chemotherapy plus lenalidomide versus autologous transplantation, followed by lenalidomide plus prednisone versus lenalidomide maintenance, in patients with multiple myeloma: a randomised, multicentre, phase 3 trial. 117
Triplet vs doublet lenalidomide-containing regimens for the treatment of elderly patients with newly diagnosed multiple myeloma 117
Autologous transplant vs oral chemotherapy and lenalidomide in newly diagnosed young myeloma patients: a pooled analysis 116
Interpretation criteria for FDG PET/CT in multiple myeloma (IMPeTUs): final results. IMPeTUs (Italian myeloma criteria for PET USe) 116
Extramedullary intracranial localization of multiple myeloma and treatment with novel agents: a retrospective survey in 50 patients 114
Successful mobilization of PBSCs predicts favorable outcomes in multiple myeloma patients treated with novel agents and autologous transplantation. 113
Long lasting remission after haploidentical stem cell transplant and pre-emptive donor lymphocyte infusions in a patient with primary refractory Hodgkin lymphoma 112
Cytokines dysregulation and chronic graft versus host disease after allogeneic haematopoieitc stem cell transplantation with reduced intensity conditioning 111
A retrospective analysis of 144 patients with aggressive non-Hodgkin's lymphoma: impact of aurtologoaus stem cell transplantation in first remission on autcome 110
Real-world study in steroid-refractory acute graft versus host disease: Comparison of efficacy and tolerability of ruxolitinib alone or ruxolitinib in association with extracorporeal photopheresis or extracorporeal photopheresis monotherapy 109
Lamivudine allows completion of chemotherapy in lymphoma patients with hepatitis B reactivation 109
Multiple Myeloma: presenting features and survival according to hospital referral 108
Sequential study of cytokine and lymphocyte patterns in patients with chronic agraft versus host disease after reduced intensity conditioning allogenic stem cell transplantation 108
Complete response correlates with long-term progression-free and overall survival in elderly myeloma treated with novel agents: analysis of 1175 patients 108
Factors predicting outcome after allogeneic transplant in refractory acute myeloid leukemia: a retrospective analysis of Gruppo Italiano Trapianto di Midollo Osseo (GITMO) 108
High dose therapy with stem cell rescue in elderly atients with aggressive poor risk lymphomas: a review of 14 cases. 107
Hepatitis C virus infection among cryoglobulinemic and non-cryoglobulinemic B-cell non-Hodgkin’s lymphomas 107
Prognostic significance of delayed thrombocytopenia after allogeneic stem cell transplant 107
Bortezomib induction, reduced-intensity transplantation, and lenalidomide consolidation-maintenance for myeloma: updated results. 107
Consensus statement from European experts on the diagnosis, management, and treatment of multiple myeloma: from standard therapy to novel approaches. 107
Qualitative and quantitative polymerase chain reaction monitoring minimal residual disease in relapsed chronic lymphocytic leukemia: early assessment can predict long-term outcome after reduced intensity allogeneic transplantation . 107
FEASIBILITY AND OUTCOME OF ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION IN PATIENTS OLDER THAN 60 YEARS WITH POOR RISK ACUTE MYELOID LEUKEMIA 106
Efficacy and safety of once-weekly bortezomib in multiple myeloma patients. 106
The CIBMTR score predicts survival of AML patients undergoing allogeneic transplantation with active disease after a myeloablative or reduced intensity conditioning: a retrospective analysis of the Gruppo Italiano Trapianto Di Midollo Osseo. 106
Allogeneic transplantation improves the overall and progression-free survival of Hodgkin lymphoma patients relapsing after autologous: a retrospective study based on the time of HLA typing and donor availability 105
Kinetics of Th1/Th2 cytokines and lymphocyte subsets to predict chronic GVHD after allo-SCT: results of a prospective study. 105
Treatment of refractory chronic GVHD with rituximab: a GITMO study 105
Sirolimus-based graft-versus-host disease prophylaxis promotes the in vivo expansion of regulatory T cells and permits peripheral blood stem cell transplantation from haploidentical donors. 105
Improvement of amyloid-related symptoms after autologous stem cell transplantation in a patient with hepatomegaly, macroglossia and purpura 104
The hematopoietic cell transplantation comorbidity index (HCT-CI) predicts clinical outcomes in lymphoma and myeloma patients after reduced-intensity or non-myeloablative allogeneic stem cell transplantation 104
A prospective comparison of 18 F-fluorodeoxyglucose positron emission tomography-computed tomography, magnetic resonance imaging and whole-body planar radiographs in the assessment of bone disaese in newly diagnosed multiple myeloma 104
Autologous transplantation and maintenance therapy in multiple myeloma 104
Experts' considerations on HLA-haploidentical stem cell transplantation. 104
Long-term outcome and prospective validation of NIH response criteria in 39 patients receiving imatinib for steroid-refractory chronic GVHD. 104
Incidence, outcome, and risk factors of late-onset noninfectious pulmonary complications after unrelated donor stem cell transplantation 103
Considerations in the treatment of multiple myeloma: a consensus statement from Italian experts 103
Non-myeloablative allografting for newly diagnosed multiple myeloma: the experience of the Gruppo Italiano Trapianti di Midollo 103
Thalidomide-dexamethasone as up-front therapy for patients with newly diagnosed multiple myeloma: thrombophilic alterations, thrombotic complications, and thromboprophylaxis with low-dose warfarin. 103
Combination of international scoring system 3, high lactate dehydrogenase, and t(4;14) and/or del(17p) identifies patients with multiple myeloma (MM) treated with front-line autologous stem-cell transplantation at high risk of early MM progression-related death. 103
Lenalidomide can induce long-term responses in patients with multiple myeloma relapsing after multiple chemotherapy lines, in particular after allogeneic transplant 102
Totale 13.022
Salva come PNG Salva come JPEG
Categoria #
all - tutte 88.378
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 88.378
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/20211.807 0 0 0 0 0 354 234 328 317 104 288 182
2021/20221.611 68 205 85 102 37 69 101 77 15 269 328 255
2022/20231.465 224 73 13 177 142 428 1 103 220 17 32 35
2023/2024489 64 28 10 17 67 53 25 43 81 46 26 29
2024/20253.788 86 285 121 89 295 190 184 240 351 368 551 1.028
2025/20264.007 547 783 681 791 988 217 0 0 0 0 0 0
Totale 22.616